SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Heart Failure | SGLT2 Inhibitors | Study